The somatostatin analog (SSA) pasireotide, which has 40-fold greater binding affinity to SST5 compared to first-generation SSAs, shows promising results in case reports of DA-resistant prolactinomas. Here, SSTR5 is linked to prolactin-producing pituitary gland adenoma.